Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +972-77-2005042 from 8 AM - 11 PM IL

      • Contact
      • Contact

        +972-77-2005042
        from 8 AM - 11 PM IL

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Request More Information
      • Journalists
      • GDPR

      InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

      InMode Ltd.

      News provided by

      InMode Ltd.

      24 Oct, 2024, 14:03 IDT

      Share this article

      Share this article


      IRVINE, Calif., Oct. 24, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has been granted a preliminary injunction by the U.S. District Court for the Central District of California in a lawsuit filed against sellers identified to be the source of unlawful counterfeit sales of Morpheus8 radiofrequency devices and cartridge accessories. 

      Continue Reading
      InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories
      InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

      On September 3, 2024, the Honorable Michael Fitzgerald of the U.S. District Court for the Central District of California issued the order granting InMode's motion for a preliminary injunction.  InMode's large-scale action against these illegitimate sellers also warranted a Temporary Restraining Order (TRO), which was granted due to strong supporting evidence that it is within the public interest to protect InMode's trademarks and prevent the sale of counterfeit products, particularly in this case, where Defendants' counterfeit Morpheus8 products could be sold to unsuspecting third parties for use in medical procedures. As a result, a court-ordered preliminary injunction has been issued, freezing various assets, and account listings of all sellers involved in the sale of the aforementioned counterfeit goods.

      "InMode has zero tolerance for dishonest business practices and considers the safety of the public its number one priority," said Moshe Mizrahy, CEO of InMode. "We will take necessary action with online platforms and sellers participating in the irresponsible use, sale or distribution of our brand and counterfeit products associated with it."

      InMode will continue to relentlessly pursue enforcement against sellers of counterfeit InMode products and Morpheus8 devices and accessories to address the harm and adverse reactions caused by counterfeit Morpheus8 devices. In the United States, patients can confirm they are receiving top-quality care from an InMode provider using a genuine Morpheus8 device by finding an authorized provider at www.inmodemd.com/find-a-provider.

      About InMode 

      InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

      Press Contact:
      Behrman Cesa Communications
      [email protected] 

      Investor Contact:
      MS-IR LLC
      Miri Segal – Scharia
      [email protected] 

      SOURCE InMode Ltd.

      Modal title

      Also from this source

      InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

      InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

      InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...

      InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

      InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

      InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announces the launch of Morpheus8 Cool, the next evolution...

      More Releases From This Source

      Contact PR Newswire

      • +972-77-2005042
        from 8 AM - 11 PM IL

      Global Sites

      • APAC
      • APAC - Traditional Chinese
      • Asia
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany

       

      • India
      • Indonesia
      • Israel
      • Italy
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland

       

      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921
      Global Sites
      • Asia
      • Brazil
      • Canada
      • Csezh
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Israel
      • Italie
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      +972-77-2005042
      from 8 AM - 11 PM IL
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • Cookie Settings
      Copyright © 2026 Cision US Inc.